Monday, February 27, 2012

Metallothionein Deficiency / Abstract and References

PAIN [The official journal of the International Association for the Study of Pain]
Volume 153, Issue 3 , Pages 532-539, March 2012





Metallothionein deficiency in the injured peripheral nerves of complex regional pain syndrome as revealed by proteomics





Summary
This work, for the first time, revealed molecules central in intractable pain in complex regional pain syndrome (CRPS). Metallothionein, a very strong free radical scavenger and an anti-inflammatory mediator is lacked in the affected nerves of CRPS. This work may shed a light in pathology of this intractable algetic disorder and open a new paradigm in this difficult condition.

Abstract
Complex regional pain syndrome (CRPS) is characterized by persistent and severe pain after trauma or surgery; however, its molecular mechanisms in the peripheral nervous system are poorly understood. Using proteomics, we investigated whether injured peripheral nerves of CRPS patients have altered protein profiles compared with control nerves. We obtained nerve samples from 3 patients with CRPS-2 who underwent resection of part of an injured peripheral nerve. Sural nerves from fresh cadavers with no history of trauma or neuropathic pain served as controls. Proteomic analysis showed that the number and functional distribution of proteins expressed in CRPS and control nerves was similar. Interestingly, metallothionein was absent in the injured nerves of CRPS-2, although it was readily detected in control nerves. Western blotting further confirmed the absence of metallothionein in CRPS-2 nerves, and immunohistochemistry corroborated the deficiency of metallothionein expression in injured nerves from 5 of 5 CRPS patients and 2 of 2 patients with painful neuromas. In contrast, all control nerves, including 5 sural nerves from fresh cadavers and 41 nerves obtained from surgically resected tumors, expressed MT. Furthermore, expression of S100 as a marker for Schwann cells, and neurofilament M as a marker of axons was comparable in both CRPS-2 and controls.

Metallothioneins are zinc-binding proteins that are probably involved in protection against injury and subsequent regeneration after CNS damage. Their absence from the injured peripheral nerves of patients with CRPS-2 suggests a potential pathogenic role in generating pain in the damaged peripheral nerves.


References 

  1. Abel J, de Ruiter N. Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. Toxicol Lett. 1989;47:191–196
  2. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA.2007;104:1307–1312
    • Bell SG, Vallee BL. The metallothionein/thionein system: an oxidoreductive metabolic zinc link. ChemBioChem. 2009;10:55–62
    • Chung JM. The role of reactive oxygen species (ROS) in persistent pain. Mol Interv. 2004;4:248–250
    • Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, Asmussen JW, et al. Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem. 2008;283:15349–15358
    • Chung RS, Vickers JC, Chuah MI, West AK. Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. J Neurosci. 2003;23:3336–3342
      • Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60:540–551
      • Ebadi M, Sharma S. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Exp Biol Med. 2006;231:1576–1583
        • Eibl JK, Abdallah Z, Ross GM. Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stress. Can J Physiol Pharmacol. 2010;88:305–312
        • Eisenberg E, Shtahl S, Geller R, Reznick AZ, Sharf O, Ravbinovich M, et al. Serum and salivary oxidative analysis in complex regional pain syndrome. Pain. 2008;138:226–232
        • Fitzgerald M, Nairn P, Bartlett CA, Chung RS, West AK, Beazley LD. Metallothionein-IIA promotes neurite growth via the megalin receptor. Exp Brain Res. 2007;183:171–180
        • Giralt M, Penkowa M, Lago N, Molinero A, Hidalgo J. Metallothionein-1+2 protect the CNS after a focal brain injury. Exp Neurol.2002;173:114–128
        • Goncalves A, Bertucci F. Clinical application of proteomics in breast cancer: state of the art and perspectives. Med Princ Pract. 2011;20:4–18
        • Gotow T. Neurofilaments in health and disease. Med Electron Microsc. 2000;33:173–199
        • Harden RN, Bruehl SP. Diagnosis of complex regional pain syndrome: signs, symptoms, and new empirically derived diagnostic criteria. Clin J Pain. 2006;22:415–419
        • Hidalgo J, Penkowa M, Espejo C, Martinez-Caceres EM, Carrasco J, Quintana A, et al. Expression of metallothionein-I, -II, and -III in Alzheimer disease and animal models of neuroinflammation. Exp Biol Med. 2006;231:1450–1458
          • Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M, et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood. 2008;111:4403–4412
          • Hu HD, Ye F, Zhang DZ, Hu P, Ren H, Li SL. ITRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells. J Biomed Biotechnol. 2010;2010:571343
            • Inoue K, Takano H, Shimada A, Satoh M. Metallothionein as an anti-inflammatory mediator. Mediat Inflamm. 2009;2009:426214
              • Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–210
              • Kerlavage A, Bonazzi V, di Tommaso M, Lawrence C, Li P, Mayberry F, et al. The Celera Discovery System™. Nucleic Acids Res.2002;30:129–136
              • Kim HK, Park SK, Zhou JL, Taglialatela G, Chung K, Coggeshall RE, et al. Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain. Pain. 2004;111:116–124
              • Koch A, Zacharowski K, Boehm O, Stevens M, Lipfert P, von Giesen HJ, et al. Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm Res. 2007;56:32–37
              • Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147:S232–S240
              • Målen H, Pathak S, Søfteland T, de Souza GA, Wiker HG. Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv. BMC Microbiol. 2010;10:132
              • Mizzen CA, Cartel NJ, Yu WH, Fraser PE, McLachlan DR. Sensitive detection of metallothioneins-1, -2 and -3 in tissue homogenates by immunoblotting: a method for enhanced membrane transfer and retention. J Biochem Biophys Methods.1996;32:77–83
              • Naik AK, Tandan SK, Dudhgaonkar SP, Jadhav SH, Kataria M, Prakash VR, et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-l-cysteine in rats. Eur J Pain. 2006;10:573–579
              • Pedersen MO, Jensen R, Pedersen DS, Skjolding AD, Hempel C, Maretty L, et al. Metallothionein-I+II in neuroprotection. BioFactors.2009;35:315–325
              • Penkowa M, Camats J, Giralt M, Molinero A, Hernandez J, Carrasco J, et al. Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression. Glia.2003;42:287–306
              • Penkowa M, Carrasco J, Giralt M, Molinero A, Hernandez J, Campbell IL, et al. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J Cereb Blood Flow Metab.2000;20:1174–1189
                • Penkowa M, Hidalgo J. Metallothionein I+II expression and their role in experimental autoimmune encephalomyelitis. Glia.2000;32:247–263
                • Penkowa M, Hidalgo J. Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp Neurol. 2001;170:1–14
                • Penkowa M, Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J Neurosci Res.2003;72:574–586
                • Puttaparthi K, Gitomer WL, Krishnan U, Son M, Rajendran B, Elliott JL. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J Neurosci.2002;22:8790–8796
                  • Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16:1267–1276
                  • Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers. 2009;14:493–501
                  • Scheede-Bergdahl C, Penkowa M, Hidalgo J, Olsen DB, Schjerling P, Prats C, et al. Metallothionein-mediated antioxidant defense system and its response to exercise training are impaired in human type 2 diabetes. Diabetes. 2005;54:3089–3094
                  • Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10:1361–1368
                  • Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.Anal Chem. 1996;68:850–858
                  • Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics. 2007;6:1638–1655
                  • Shinoda K, Tomita M, Ishihama Y. EmPAI Calc—for the estimation of protein abundance from large-scale identification data by liquid chromatography–tandem mass spectrometry. Bioinformatics. 2010;26:576–577
                  • Stankovic RK. Atrophy of large myelinated axons in metallothionein-I, II knockout mice. Cell Mol Neurobiol. 2005;25:943–953
                  • Stankovic RK, Li Z. Decreased neurofilament density in large myelinated axons of metallothionein-I, II knockout mice.Neurosci Lett. 2006;402:1–6
                  • Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995;63:127–133
                  • de Tran QH, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth. 2010;57:149–166
                  • van Lookeren Campagne M, Thibodeaux H, van Bruggen N, Cairns B, Gerlai R, Palmer JT, et al. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci USA. 1999;96:12870–12875
                    • Yamaguchi M, Kokai Y, Imai S, Utsumi K, Matsumoto K, Honda H, et al. Investigation of annexin A5 as a biomarker for Alzheimer’s disease using neuronal cell culture and mouse model. J Neurosci Res. 2010;88:2682–2692
                      • Yamashita T, Ishii S, Usui M. Pain relief after nerve resection for post-traumatic neuralgia. J Bone Joint Surg. 1998;80:499–503
                        • Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, Kumar C, et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res. 2008;7:386–399
                        at
                        Labels: , , , ,

                        No comments:

                        Post a Comment

                        The Haddock Corporation's newest dictate: Anonymous comments are no longer allowed. It is easy enough to register and just takes a moment. We look forward to hearing from you non-bots and non-spammers!

                        Subscribe to: Post Comments (Atom)